Necrobiotic xanthogranuloma: Highlighting the role of clinicopathologic correlation in an atypical presentation
DOI:
https://doi.org/10.25251/h2yhk116Keywords:
granulomatous, histopathology, necrobiotic xanthogranulomaAbstract
Necrobiotic xanthogranuloma (NXG) is a rare, chronic non–Langerhans cell histiocytosis that clinically manifests as yellow to orange papules or nodules, most commonly involving the periorbital region. Histopathologic features include necrobiotic collagen, multinucleated giant cells (including Touton and Langhans types), granulomatous inflammation with xanthomatous histiocytes, extracellular lipid, and occasionally lymphoid follicles and plasma cells. NXG has a well-documented association with monoclonal gammopathies and extracutaneous malignancies, although the underlying pathogenic mechanisms remain poorly understood. We report the case of a 72-year-old woman presenting with erythematous plaques on the abdomen and extremities. Despite the absence of classic facial involvement and an initial nondiagnostic skin biopsy, further evaluation revealed a clonal plasma cell disorder classified as borderline between monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. A subsequent biopsy demonstrated diagnostic features of NXG. This case underscores the importance of integrating clinical findings with histopathologic evaluation to achieve an accurate diagnosis.
References
1. Fernández-Herrera J, Pedraz J. Necrobiotic xanthogranuloma. Semin Cutan Med Surg. 2007;26:108-113. doi:10.1016/j.sder.2007.02.008. PMID:17544963
2. Hilal T, DiCaudo DJ, Connolly SM, Reeder CB. Necrobiotic xanthogranuloma: a 30-year single- center experience. Ann Hematol. 2018;97:1471-1479. doi:10.1007/s00277-018-3301-1. PMID:29568990
3. Bhadresha S, Cuthill K, Salisbury J, et al. A case of ulcerated nodules in association with a monoclonal gammopathy. JAAD Case Rep. 2024;54:82-84. doi:10.1016/j.jdcr.2024.07.019. PMID:39687065
4. Conforti C, Zalaudek I. Necrobiotic xanthogranuloma as sign of monoclonal gammopathy. Dermatol Pract Concept. 2022;12:e2022131. doi:10.5826/dpc.1204a131. PMID:36534574
5. Nelson CA, Zhong CS, Hashemi DA, et al. A multicenter cross-sectional study and systematic review of necrobiotic xanthogranuloma with proposed diagnostic criteria. JAMA Dermatol. 2020;156:270-279. doi:10.1001/jamadermatol.2019.4221. PMID:31940000
6. Bassir F, Valido K, Maciejewski KR, Damsky W, Nelson CA. Validation of the delphi consensus diagnostic criteria for necrobiotic xanthogranuloma. JAMA Dermatol. 2024;160:1361-1362. doi:10.1001/jamadermatol.2024.3198. PMID:39356540
7. Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol. 1980;3:257-270. doi:10.1016/s0190-9622(80)80189-7. PMID:7451693
8. Puertas B, González-Calle V, Sobejano-Fuertes E, et al. Multiple myeloma with t(11;14): impact of novel agents on outcome. Blood Cancer J. 2023;13:40. doi:10.1038/s41408-023-00807-9. PMID:36935422
9. Szalat R, Pirault J, Fermand JP, et al. Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy. J Intern Med. 2014;276:269-284. doi:10.1111/joim.12195. PMID:24428816
10. Chen PY, Tang ZL, Hong YY, et al. Genetic aspects of necrobiotic xanthogranuloma. JAMA Dermatol. 2024;160:1125-1128. doi:10.1001/jamadermatol.2024.2921. PMID:39230882
11. Claveau JS, Wetter DA, Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer J. 2022;12:58. doi:10.1038/s41408-022-00661-1. PMID:35411042
12. Hansen I, Ghandili S, Abeck F, Booken N, Schneider SW. Therapy of necrobiotic xanthogranuloma - case series and review of the literature. J Dtsch Dermatol Ges. 2023;21:1315-1318. doi:10.1111/ddg.15195. PMID:37811744
13. Steinhelfer L, Kühnel T, Jägle H, et al. Systemic therapy of necrobiotic xanthogranuloma: a systematic review. Orphanet J Rare Dis. 2022;17:132. doi:10.1186/s13023-022-02291-z. PMID:35331271
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Camille Gorena, Evan Baird, Janine Malone, Courtney R. Schadt (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.
